EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) has announced a definitive agreement for the sale of YUTIQ, their fluocinolone acetonide intravitreal implant used in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Alimera Sciences, Inc. (Nasdaq: ALIM) will acquire YUTIQ for a significant sum of $82.5 million in cash plus royalties. 

In pre-market trading, $EYPT is experiencing a notable surge, currently trading at $7.20, with an impressive gain of $0.79 (+12.32%). Similarly, $ALIM is also witnessing a significant increase in its stock price, currently trading at $2.86, with a gain of $0.80 (+38.83%). 

In another development, Protalix BioTherapeutics, Inc. (NYSE American: PLX) has disclosed that it is eligible to receive a milestone payment of $20 million from its commercial partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group. This milestone payment has been triggered by the U.S. Food and Drug Administration's (FDA) approval of ELFABRIO (pegunigalsidase alfa-iwxj), an innovative treatment for adult patients with Fabry disease. 

In pre-market trading, $PLX is currently trading at $2.37, with a marginal gain of $0.01 (+0.42%). 

Furthermore, Walmart Inc. (NYSE: WMT) has reported its financial results for the first quarter of fiscal year 2024, surpassing market expectations. The company's adjusted EPS for Q1 FY24 stood at $1.47, exceeding the consensus estimate of $1.32. 

In pre-market trading, $WMT is reflecting a positive trend, currently trading at $151.77, with a gain of $2.24 (+1.50%). 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)